Skip to main content

Closed

KROS: Keros Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Operating margin-332.6%

ROIC-34.5%

Financially safe

Stretched

Debt / equity0.06×

Interest coverage0.0×

Current ratio22.62×

Keros Therapeutics, Inc.

KROSNASDAQ Global Market·USD·Closed

Keros Therapeutics, Inc.

KROSNASDAQ·USD·Closed

$10.07

−1.47%

$10.07

−$0.15 (1.47%)

52W Range

3thpctl

Volume

0.49×avg

Mkt Cap

322.22MUSD

P/E

-4.1TTM

Div Yield

–ann

52W Range

3thpctl

Volume

0.49×avg

Market Cap

322.22MUSD

P/E Ratio

-4.1TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings